RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and cancer. Utilizing our proprietary drug discovery and development engine, we develop highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. Since our founding, we have discovered and advanced to clinical development two drug candidates, each targeting CCR4. In a randomized, placebo-controlled Phase 1b study in patients with atopic dermatitis, our lead inflammation drug candidate, RPT193, demonstrated clinically meaningful improvement in several exploratory endpoints. Our lead oncology drug candidate, FLX475, is in development for a range of tumors. We are also pursuing a range of other targets, including HPK1, that are in earlier stages of discovery and development.
Data Provided by Refinitiv. Minimum 15 minutes delayed.